Direct Clinical Pharmacist-Patient Telephone Follow-Up: A Focus on GI Medical Oncology Symptom Management
JCO Oncology Practice · 2024
DOI: 10.1200/op.23.00452 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Oncology Practice, 2024. Verfasst von Jane E Rogers und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Clinical Programs, The University of Texas MD Anderson Cancer Center, Houston, TX. Hauptthemen laut MEDLINE: Telephone, Pharmacists, Medical Oncology. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben.
Abstract (Originalsprache)
PURPOSE GI medical oncology care presents unique medication challenges. Here, we captured our clinical pharmacy specialists' (CPSs) involvement in patients with GI cancers starting cycle 1 of a new treatment. METHODS Our quality initiative was performed in three stages (preintervention, intervention, and postintervention). Preintervention: retrospective baseline data collection from May to December 2019. Intervention: one-time telephone encounters were conducted by a CPS between March 15 and June 11, 2021. The primary objective of the quality improvement initiative was to increase patient interaction with a CPS to 80%. Postintervention: data collection to review the impact of CPS telephone encounters. RESULTS Preintervention: we reviewed the electronic health records of 262 patients. Sixty nine percent of patients reported at least one adverse event (AE; range 1-6 AEs) at the first physician follow-up after treatment start. Most reported AEs (78%) were considered modifiable within the scope of CPS practice. Postintervention: during the intervention, 92% of patients (n = 389) received a telehealth encounter with the CPS. At the encounter, 315 patients (81%) reported at least one AE. CPS provided recommendations and/or additional education for 88% of reported AEs. Medication lists required correction 75% of the time. The median time for CPS encounters (including documentation) was 40 minutes. CONCLUSION During a 3-month period, this quality improvement initiative successfully provided an early CPS-based telehealth intervention to identify and make initial recommendations for management of AEs for patients on cycle 1 of systemic therapy for GI cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Pharmacy Clinical Programs, The University of Texas MD Anderson Cancer Center, Houston, TX.
- Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX.
ORCID-Profile: Jane E Rogers, Jennifer Zadlo, Cheuk Hong Leung, Morgan Mace, Makenna Smack, Amanda Sirisaengtaksin, Stacy Diao, Zhou Fang
Zitieren
APA
Rogers, J. E., Zadlo, J., Leung, C. H., Nguyen, V., Leung, M., Mace, M., Covert, W., Smack, M., Sirisaengtaksin, A., Diao, S., Fang, Z., & Landgraf Oholendt, A. (2024). Direct Clinical Pharmacist-Patient Telephone Follow-Up: A Focus on GI Medical Oncology Symptom Management. JCO Oncology Practice. https://doi.org/10.1200/op.23.00452
Vancouver
Rogers JE, Zadlo J, Leung CH, Nguyen V, Leung M, Mace M, et al. Direct Clinical Pharmacist-Patient Telephone Follow-Up: A Focus on GI Medical Oncology Symptom Management. JCO Oncology Practice. 2024. doi:10.1200/op.23.00452
BibTeX
@article{Rogers2024,
author = {Rogers, Jane E and Zadlo, Jennifer and Leung, Cheuk Hong and Nguyen, Van and Leung, Michael and Mace, Morgan and Covert, Wendy and Smack, Makenna and Sirisaengtaksin, Amanda and Diao, Stacy and Fang, Zhou and Landgraf Oholendt, Andrea},
title = {Direct Clinical Pharmacist-Patient Telephone Follow-Up: A Focus on GI Medical Oncology Symptom Management},
journal = {JCO Oncology Practice},
year = {2024},
doi = {10.1200/op.23.00452}
}
EUVIMED